메뉴 건너뛰기




Volumn 36, Issue 4, 2011, Pages 273-280

Fostamatinib disodium: Tyrosine-protein kinase SYK/FLT3 inhibitor treatment of rheumatoid arthritis oncolytic

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; FC RECEPTOR; FOSTAMATINIB; METHOTREXATE; NSC 745942; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG;

EID: 84952976693     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.04.1588554     Document Type: Review
Times cited : (46)

References (39)
  • 1
    • 84952980031 scopus 로고    scopus 로고
    • Pyrimidinediamine kinase inhibitors
    • Rigel Pharmaceuticals, Inc. US 2010179134, WO 2010078369
    • Singh, R., Atuegbu, A., Ramphal, J. et al. (Rigel Pharmaceuticals, Inc.). Pyrimidinediamine kinase inhibitors. US 2010179134, WO 2010078369.
    • Singh, R.1    Atuegbu, A.2    Ramphal, J.3
  • 2
    • 84952989344 scopus 로고    scopus 로고
    • Synthesis of N4-(2,2-dimethyl-4-[dihydrogen phosphonoxy]-3-oxo-5- pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2, 4-pyrimidinediamine disodium salt
    • Rigel Pharmaceuticals, Inc.. US 2011003986, WO 2011002999
    • Felfer, U., Giselbrecht, K.-H., Wolberg, M. (Rigel Pharmaceuticals, Inc.). Synthesis of N4-(2,2-dimethyl-4-[dihydrogen phosphonoxy]-3-oxo-5- pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2, 4-pyrimidinediamine disodium salt. US 2011003986, WO 2011002999.
    • Felfer, U.1    Giselbrecht, K.-H.2    Wolberg, M.3
  • 3
    • 80052960249 scopus 로고    scopus 로고
    • Prodrug salts of 2,4-pyrimidinediamine compounds and their uses
    • Rigel Pharmaceuticals, Inc. EP 2078026, JP 2010510322, WO 2008064274
    • Bhamidipati, S., Singh, R., Sun, T., Masuda, E. (Rigel Pharmaceuticals, Inc.). Prodrug salts of 2,4-pyrimidinediamine compounds and their uses. EP 2078026, JP 2010510322, WO 2008064274.
    • Bhamidipati, S.1    Singh, R.2    Sun, T.3    Masuda, E.4
  • 4
    • 80052960249 scopus 로고    scopus 로고
    • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    • Rigel Pharmaceuticals, Inc.. CA 2591948, EP 1856135, EP 2161275, JP 2008527048, US 2006211657, US 7449458, WO 2006078846
    • Singh, R., Bhamidipati, S., Masuda, E., Stella, V.J., Sun, T. (Rigel Pharmaceuticals, Inc.). Prodrugs of 2,4-pyrimidinediamine compounds and their uses. CA 2591948, EP 1856135, EP 2161275, JP 2008527048, US 2006211657, US 7449458, WO 2006078846.
    • Singh, R.1    Bhamidipati, S.2    Masuda, E.3    Stella, V.J.4    Sun, T.5
  • 5
    • 80052960249 scopus 로고    scopus 로고
    • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    • Rigel Pharmaceuticals, Inc.. US 7563892
    • Singh, R., Bhamidipati, S., Stella, V.J., Sun, T. (Rigel Pharmaceuticals, Inc.). Prodrugs of 2,4-pyrimidinediamine compounds and their uses. US 7563892.
    • Singh, R.1    Bhamidipati, S.2    Stella, V.J.3    Sun, T.4
  • 7
    • 0033997615 scopus 로고    scopus 로고
    • Tyrosine kinase SYK: Essential functions for immunoreceptor signalling
    • DOI 10.1016/S0167-5699(99)01574-1, PII S0167569999015741
    • Turner, M., Schweighoffer, E., Colucci, F., Di Santo, J.P., Tybulewicz, V.L. Tyrosine kinase SYK: Essential functions for immunoreceptor signalling. Immunol Today 2000, 21(3): 148-54. (Pubitemid 30122705)
    • (2000) Immunology Today , vol.21 , Issue.3 , pp. 148-154
    • Turner, M.1    Schweighoffer, E.2    Colucci, F.3    Di, S.J.P.4    Tybulewicz, V.L.5
  • 8
    • 77952887713 scopus 로고    scopus 로고
    • The SYK tyrosine kinase: A crucial player in diverse biological functions
    • Mocsai, A., Ruland, J., Tybulewicz, V.L. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol 2010, 10(6): 387-402.
    • (2010) Nat Rev Immunol , vol.10 , Issue.6 , pp. 387-402
    • Mocsai, A.1    Ruland, J.2    Tybulewicz, V.L.3
  • 9
    • 33751197936 scopus 로고    scopus 로고
    • R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation
    • Braselmann, S., Taylor, V., Zhao, H. et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006, 319(3): 998-1008.
    • (2006) J Pharmacol Exp Ther , vol.319 , Issue.3 , pp. 998-1008
    • Braselmann, S.1    Taylor, V.2    Zhao, H.3
  • 10
    • 33645867986 scopus 로고    scopus 로고
    • A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes
    • Cha, H.S., Boyle, D.L., Inoue, T., Schoot, R., Tak, P.P., Pine, P., Firestein, G.S. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006, 317(2): 571-8.
    • (2006) J Pharmacol Exp Ther , vol.317 , Issue.2 , pp. 571-578
    • Cha, H.S.1    Boyle, D.L.2    Inoue, T.3    Schoot, R.4    Tak, P.P.5    Pine, P.6    Firestein, G.S.7
  • 11
    • 67650458526 scopus 로고    scopus 로고
    • Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia
    • Buchner, M., Fuchs, S., Prinz, G. et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009, 69(13): 5424-32.
    • (2009) Cancer Res , vol.69 , Issue.13 , pp. 5424-5432
    • Buchner, M.1    Fuchs, S.2    Prinz, G.3
  • 12
    • 41349110211 scopus 로고    scopus 로고
    • SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
    • DOI 10.1182/blood-2007-07-100115
    • Chen, L.,Monti, S., Juszczynski, P. et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111(4): 2230-7. (Pubitemid 351451430)
    • (2008) Blood , vol.111 , Issue.4 , pp. 2230-2237
    • Chen, L.1    Monti, S.2    Juszczynski, P.3    Daley, J.4    Chen, W.5    Witzig, T.E.6    Habermann, T.M.7    Kutok, J.L.8    Shipp, M.A.9
  • 13
    • 70349237504 scopus 로고    scopus 로고
    • B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406
    • Quiroga, M.P., Balakrishnan, K., Kurtova, A.V. et al., B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009, 114(5): 1029-37.
    • (2009) Blood , vol.114 , Issue.5 , pp. 1029-1037
    • Quiroga, M.P.1    Balakrishnan, K.2    Kurtova, A.V.3
  • 14
    • 77952886100 scopus 로고    scopus 로고
    • Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
    • Buchner, M., Baer, C., Prinz, G. et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood, 2010, 115(22): 4497-506.
    • (2010) Blood , vol.115 , Issue.22 , pp. 4497-4506
    • Buchner, M.1    Baer, C.2    Prinz, G.3
  • 15
    • 45949094157 scopus 로고    scopus 로고
    • Costimulation of dectin-1 and DC-SIGN triggers the arachidonic acid cascade in human monocyte-derived dendritic cells
    • Valera, I., et al., Costimulation of dectin-1 and DC-SIGN triggers the arachidonic acid cascade in human monocyte-derived dendritic cells. J Immunol 2008, 180(8): 5727-36.
    • (2008) J Immunol , vol.180 , Issue.8 , pp. 5727-5736
    • Valera, I.1
  • 16
    • 33645676304 scopus 로고    scopus 로고
    • Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation
    • Matsubara, S., Koya, T., Takeda, K. et al. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol, 2006, 34(4): p. 426-33.
    • (2006) Am J Respir Cell Mol Biol , vol.34 , Issue.4 , pp. 426-433
    • Matsubara, S.1    Koya, T.2    Takeda, K.3
  • 17
    • 77956417942 scopus 로고    scopus 로고
    • Therapeutic targeting of Syk in autoimmune diabetes
    • Colonna, L., Catalano, G., Chew, C. et al. Therapeutic targeting of Syk in autoimmune diabetes. J Immunol 2010, 185(3): 1532-43.
    • (2010) J Immunol , vol.185 , Issue.3 , pp. 1532-1543
    • Colonna, L.1    Catalano, G.2    Chew, C.3
  • 18
    • 77349087551 scopus 로고    scopus 로고
    • Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells
    • Sanderson, M.P., Gelling, S.J., Rippmann, J.F., Schnapp, A. Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells. Cell Immunol 2010, 262(1): 28-34.
    • (2010) Cell Immunol , vol.262 , Issue.1 , pp. 28-34
    • Sanderson, M.P.1    Gelling, S.J.2    Rippmann, J.F.3    Schnapp, A.4
  • 19
    • 71849102938 scopus 로고    scopus 로고
    • Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells
    • Krishnan, S., Juang, Y.T., Chowdhury, B. et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 2008, 181(11): 8145-52.
    • (2008) J Immunol , vol.181 , Issue.11 , pp. 8145-8152
    • Krishnan, S.1    Juang, Y.T.2    Chowdhury, B.3
  • 20
    • 46749088793 scopus 로고    scopus 로고
    • An orally bioavailable inhibitor of FLT3 and Syk kinases prevents tumor growth in subcutaneously implanted human tumor xenografts and promotes cell death of FLT3 mutant AML cells
    • thAnnu Meet Am Soc Hematol (December 10-13, Atlanta) 2005 Abst 243
    • thAnnu Meet Am Soc Hematol (December 10-13, Atlanta) 2005], 2005, 106(11): Abst 243.
    • (2005) Blood , vol.106 , Issue.11
    • Pine, P.R.1
  • 21
    • 67649494454 scopus 로고    scopus 로고
    • The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets
    • Spalton, J.C., Mori, J., Pollitt, A.Y., Hughes, C.E., Eble, J.A., Watson, S.P. The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. J Thromb Haemost 2009, 7(7): 1192-9.
    • (2009) J Thromb Haemost , vol.7 , Issue.7 , pp. 1192-1199
    • Spalton, J.C.1    Mori, J.2    Pollitt, A.Y.3    Hughes, C.E.4    Eble, J.A.5    Watson, S.P.6
  • 22
    • 78649759107 scopus 로고    scopus 로고
    • The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
    • Suljagic, M., Longo, P.G., Bennardo, S., Perlas, E., Leone, G., Laurenti, L., Efremov, D.G. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010, 116(23): 4894-905.
    • (2010) Blood , vol.116 , Issue.23 , pp. 4894-4905
    • Suljagic, M.1    Longo, P.G.2    Bennardo, S.3    Perlas, E.4    Leone, G.5    Laurenti, L.6    Efremov, D.G.7
  • 23
    • 63849309885 scopus 로고    scopus 로고
    • Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target
    • Young, R.M., Hardy, I.R., Clarke, R.L. et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009, 113(11): 2508-16.
    • (2009) Blood , vol.113 , Issue.11 , pp. 2508-2516
    • Young, R.M.1    Hardy, I.R.2    Clarke, R.L.3
  • 24
    • 65349104905 scopus 로고    scopus 로고
    • Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk
    • Podolanczuk, A., Lazarus, A.H., Crow, A.R., Grossbard, E., Bussel, J.B. Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009, 113(14): 3154-60.
    • (2009) Blood , vol.113 , Issue.14 , pp. 3154-3160
    • Podolanczuk, A.1    Lazarus, A.H.2    Crow, A.R.3    Grossbard, E.4    Bussel, J.B.5
  • 28
    • 77954229590 scopus 로고    scopus 로고
    • Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice
    • Deng, G.M., Liu, L., Bahjat, F.R., Pine, P.R., Tsokos, G.C. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010, 62(7): 2086-92.
    • (2010) Arthritis Rheum , vol.62 , Issue.7 , pp. 2086-2092
    • Deng, G.M.1    Liu, L.2    Bahjat, F.R.3    Pine, P.R.4    Tsokos, G.C.5
  • 29
    • 77949363952 scopus 로고    scopus 로고
    • A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis
    • Smith, J., McDaid, J.P., Bhangal, G. et al. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol 2010, 21(2): 231-6.
    • (2010) J Am Soc Nephrol , vol.21 , Issue.2 , pp. 231-236
    • Smith, J.1    McDaid, J.P.2    Bhangal, G.3
  • 31
    • 77951002653 scopus 로고    scopus 로고
    • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    • Friedberg, J.W., Sharman, J., Sweetenham, J. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13): 2578-85.
    • (2010) Blood , vol.115 , Issue.13 , pp. 2578-2585
    • Friedberg, J.W.1    Sharman, J.2    Sweetenham, J.3
  • 32
    • 55849114400 scopus 로고    scopus 로고
    • Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
    • Weinblatt, M.E., Kavanaugh, A., Burgos-Vargas, R. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008, 58(11): 3309-18.
    • (2008) Arthritis Rheum , vol.58 , Issue.11 , pp. 3309-3318
    • Weinblatt, M.E.1    Kavanaugh, A.2    Burgos-Vargas, R.3
  • 33
    • 77953742534 scopus 로고    scopus 로고
    • Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation
    • Sweeny, D.J., Li, W., Clough, J. et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: Contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 2010, 38(7): 1166-76.
    • (2010) Drug Metab Dispos , vol.38 , Issue.7 , pp. 1166-1176
    • Sweeny, D.J.1    Li, W.2    Clough, J.3
  • 36
    • 78650294662 scopus 로고    scopus 로고
    • An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritisthat did not respond to biologic agents
    • Genovese, M.C., Kavanaugh, A., Weinblatt, M.E. et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritisthat did not respond to biologic agents. Arthritis Rheum 2010, 63(2): 337-45.
    • (2010) Arthritis Rheum , vol.63 , Issue.2 , pp. 337-345
    • Genovese, M.C.1    Kavanaugh, A.2    Weinblatt, M.E.3
  • 37
    • 62949223071 scopus 로고    scopus 로고
    • Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing
    • Clemens, G.R., Schroeder, R.E., Magness, S.H. et al. Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol 2009, 85(2): 130-6.
    • (2009) Birth Defects Res A Clin Mol Teratol , vol.85 , Issue.2 , pp. 130-136
    • Clemens, G.R.1    Schroeder, R.E.2    Magness, S.H.3
  • 38
    • 33646674509 scopus 로고    scopus 로고
    • A multiple dose study of an orally bioavailable inhibitor of Syk-kinase (R406) in human volunteers: Safety, pharmacokinetics, and pharmacodynamics
    • th Annu Sci Meet Am Coll Rheumatol (Nov 12-17, San Diego) 2005 Abst 1864
    • th Annu Sci Meet Am Coll Rheumatol (Nov 12-17, San Diego) 2005] 2005, 52(9): Abst 1864.
    • (2005) Arthritis Rheum , vol.52 , Issue.9
    • Grossbard, E.1
  • 39
    • 55849100500 scopus 로고    scopus 로고
    • A phase I randomized, double-blind, placebo-controlled, pharmacokinetic study of R788/406 and methotrexate in sixteen patients with rheumatoid arthritis
    • Abst 939
    • Grossbard, E., Baluom, M., Kivitz, A.J. A phase I randomized, double-blind, placebo-controlled, pharmacokinetic study of R788/406 and methotrexate in sixteen patients with rheumatoid arthritis. Arthritis Rheum 2006, 54(9, Suppl.): Abst 939.
    • (2006) Arthritis Rheum , vol.54 , Issue.9 SUPPL.
    • Grossbard, E.1    Baluom, M.2    Kivitz, A.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.